ArticleJournal of neurology2026
Soluble TIM-3 and galectin-9 serve as additional diagnostic biomarkers in primary central nervous system lymphoma.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic orchestration of the primary central nervous system lymphoma microenvironment.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPrimary central nervous system lymphoma (PCNSL) is a rare and aggressive B-cell lymphoma in which early diagnosis remains challenging. Although cerebrospinal fluid (CSF) B-cell-associated factors including soluble interleukin-2 receptor subunit alpha (IL-2RA) are known diagnostic markers, they often reflect neuroinflammation and are insufficient on their own to reliably differentiate PCNSL from neuroimmunological diseases. On the other hand, CSF immune checkpoint molecules reflect neuro-immune regulation and remain incompletely evaluated as biomarkers for PCNSL. We aimed to determine whether CSF immune checkpoint molecules can serve as additional diagnostic and prognostic biomarkers for PCNSL alongside B-cell-associated factors.
methodsIn this retrospective cohort study, CSF samples from 33 patients with PCNSL and 85 patients with control diseases, including neuroimmunological diseases and other brain tumors, were analyzed using a bead-based multiplex immune-assay. Correlations between markers were evaluated using Spearman's rank correlation and hierarchical clustering. Diagnostic performance was assessed using logistic regression modeling. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method.
resultsCSF levels of B-cell-associated factors (interleukin-10, C-X-C motif chemokine ligand 13, and IL-2RA) and immune checkpoint molecules (Fas ligand, T-cell immunoglobulin and mucin domain 3 (TIM-3), and galectin-9) were significantly elevated in PCNSL compared with control diseases. Correlation and cluster analysis identified two distinct marker clusters: B-cell-associated factors and immune checkpoint molecules. Two-marker diagnostic models combining IL-10 and immune checkpoint molecules demonstrated superior diagnostic performance. Higher levels of B-cell-associated factors showed a non-significant trend towards shorter PFS.
conclusionsCSF TIM-3 and galectin-9 represented additional diagnostic biomarkers for PCNSL alongside B-cell-associated factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.